Lord, Abbett & Co. LLC Amylyx Pharmaceuticals, Inc. Transaction History

Lord, Abbett & Co. LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Oct 07, 2024	SELL	$20.98 - $31.42 $116,418 - $174,349	-5,549 Reduced 2.22%	244,493 $5.27 Million
Q2 2023 Aug 14, 2023	SELL	$20.98 - $31.42 $116,418 - $174,349	-5,549 Reduced 2.22%	244,493 $5.27 Million
Q1 2023 Oct 07, 2024	BUY	$27.71 - $40.93 $6.93 Million - $10.2 Million	250,042 New	250,042 $7.34 Million
Q1 2023 May 12, 2023	BUY	$27.71 - $40.93 $6.93 Million - $10.2 Million	250,042 New	250,042 $7.34 Million

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $310M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.